What's in St. Anna Kinderkrebsforschung's pipeline?

St. Anna Kinderkrebsforschung has 4 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with St. Anna Kinderkrebsforschung's portfolio?

Top competitors by shared drug class: Hospices Civils de Lyon, Memorial Sloan Kettering Cancer Center, Asahi Kasei Pharma Corporation, Assistance Publique Hopitaux De Marseille, Astellas Pharma China, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/st-anna-kinderkrebsforschung.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

St. Anna Kinderkrebsforschung — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

St. Anna Kinderkrebsforschung pipeline: 1 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Grafalon	Grafalon	marketed			Other
VP16, ATG	VP16, ATG	phase 3	Alkylating agent	Topoisomerase II	Oncology
Fludarabine, OKT3, Treosulfan, Thiotepa	Fludarabine, OKT3, Treosulfan, Thiotepa	phase 3	Multi-agent conditioning regimen (purine analog, monoclonal antibody, alkylating agents)	dTMP synthase (fludarabine); CD3 (OKT3); DNA (treosulfan, thiotepa)	Oncology / Hematology

Therapeutic area mix

Oncology · 2
Oncology / Hematology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hospices Civils de Lyon · 2 shared drug classes
Memorial Sloan Kettering Cancer Center · 2 shared drug classes
Asahi Kasei Pharma Corporation · 1 shared drug class
Assistance Publique Hopitaux De Marseille · 1 shared drug class
Astellas Pharma China, Inc. · 1 shared drug class
Baxter · 1 shared drug class
BeBetter Med Inc · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for St. Anna Kinderkrebsforschung:

Cite this brief

Drug Landscape (2026). St. Anna Kinderkrebsforschung — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/st-anna-kinderkrebsforschung. Accessed 2026-05-17.